Central nervous system neoplasm

4 trials 2 recruiting MedDRA PT
4 Registered trials
2 Recruiting
4 Unique sponsors
5 Unique IMPs
4 Commercial trials
Drug classes (ATC)
V Various (ATC V) 1
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Kinase inhibitor 2 substances
Radiopharmaceutical 1 substance
Phase I/II: 3 Phase I (Other): 1

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase I/II

3 trials
  • Apollomics Inc. Commercial
    APL-101
    2024-514542-37-00 4 countries 2020 n=271
    Recruiting
  • Bayer Consumer Care AG Commercial
    LAROTRECTINIB SULFATE
    2022-502668-20-00 9 countries 2017 n=73
    Ended
  • Loxo Oncology Inc. Commercial
    SELPERCATINIB
    2023-507703-63-00 5 countries 2020 n=25
    Ended

Phase I (Other)

1 trial
  • ITM Solucin GmbH Commercial
    L-LYSINE HYDROCHLORIDE, L-ARGININE HYDROCHLORIDE; LUTETIUM (177LU) EDOTREOTIDE
    2024-512831-66-00 3 countries 2025 n=16 Orphan
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
ITM Solucin GmbH Commercial 1 Phase I (Other) 1
Apollomics Inc. Commercial 1 Phase I/II 1
Bayer Consumer Care AG Commercial 1 Phase I/II 0
Loxo Oncology Inc. Commercial 1 Phase I/II 0
New trials by year
2020
2
2025
1
← All indication landscapes